Impact of Chronic Glucocorticoid Treatment on Cardiovascular Risk Profile in @entity1 with XXXX .

@entity1 @entity731 @entity1252
BACKGROUND: @entity1252 is highly associated with premature @entity731 and cardiovascular events. The origin of this subclinical @entity731 has been attributed mainly to the inflammatory nature of the disease. OBJECTIVE: To assess the effect of long-term use of glucocorticoids on cardiovascular risk in @entity1 with @entity1252 . MATERIAL AND METHODS: We conducted a registry-based retrospective cohort study. We determined 2 periods: (1) Time 0, that is, time of diagnosis and (2) time 1, that is, when the study was finalized. At both times, the cardiovascular risk was evaluated using the Framingham scale and their scores were compared. Afterward, the change magnitude between the 2 times was evaluated and associated with the cumulative glucocorticoids dose. RESULTS: One hundred one @entity1 were included. The mean    SD age was 26.5    5 years. Length of disease evolution was of 7.8    4.9 years. There was an 8-point increase in the Framingham score, from -8.1    4 to 0.8    7; P < 0.0001. The correlation between the magnitude of the increase in Framingham score and their corresponding cumulative dose showed a coefficient of 0.88; P < 0.001. CONCLUSIONS: The glucocorticoids are a primary factor that influences cardiovascular risk. There is a directly proportional relationship between the cumulative glucocorticoid dose and the increase in cardiovascular risk.
